Trial
NCT05714553
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
NuCana plc
Collaborators
—
Condition
Advanced Cancer
Intervention
Fosifloxuridine Nafalbenamide
Why stopped
The NuTide:303 study was terminated at NuCana's discretion due to refinement of the pipeline strategy. The overall risk benefit assessment of NUC-3373 remains positive and future NUC-3373 studies are under consideration.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-18